When you purchase through links on our site , we may earn an affiliate commission . Here ’s how it works .
A coronavirus variant identified in South Africa may not be as vulnerable to COVID-19 vaccines as other strains , some scientist say .
Studies are now underway to find out if that ’s actually the case .
If the variant , known as 501.V2 , is repellent to availablevaccines , the shot could be tweak to further their effectiveness — adjustment tht would take about six hebdomad to make , vaccine developer assure Reuters . These developer include BioNTech CEO Dr. Uğur Şahin and John Bell , Regius Professor of Medicine at the University of Oxford , who are presently bleed experiment with both 501.V2 and the newcoronavirus variant identified in the U.K. , bring up B.1.1.7 .
These experiment are so - called neutralizing check — experiments in which they brood the viruses withantibodiesand human cells , to see if theantibodiesprevent contagion , The Associated Press ( AP ) report . They are launch the test with blood from vaccinated people and those who caught thevirusand developed antibodies of course , Dr. Richard Lessells , an infectious diseases expert who is working on South Africa ’s genomic studies of 501.V2 , order the AP .
Related:20 of the high-risk epidemics and pandemic in history
In general , it ’s not surprising that variants like 501.V2 and B.1.1.7 have emerged ; all viruses pick upmutationsas they make copy of themselves , and the novel coronavirus call SARS - CoV-2 is no exception . However , while the two latterly distinguish variants deal a few similar mutation , and 501.V2 " has a telephone number extra mutations … which are come to , " Simon Clarke , an associate professor in cellular microbiology at the University of Reading , told Reuters .
Specifically , the variant find in South Africa has more mutant in its spike protein — which perplex out from the virus ’s control surface and is used to encroach upon human cellphone — than B.1.1.7 does , Lawrence Young , a virologist and prof of molecular oncology at Warwick University , told Reuters . Most uncommitted vaccine train the resistant scheme to recognize this spike protein . If the spike protein accumulates too many mutations , it may become unrecognizable to the immune system , earmark the virus to avoid espial in the body ; this is the likely business organization with the newfangled variant 501.V2 , Young read .
— 11 ( sometimes ) pernicious diseases that hopped across species
— 14 coronavirus myth busted by science
— The 12 deadliest viruses on Earth
That said , neutralizing assays should before long reveal whether or not we need to worry . As of now , Public Health England , an executive agency of the Department of Health and Social Care , said that there is currently no evidence to advise COVID-19 vaccines wo n’t protect against both B.1.1.7 and 501.V2 , Reuters describe .
In add-on , several expert toldThe New York Timesthat it would probably take yr , not months , for the coronavirus to mutate enough to outwit available vaccines .
" It is lead to be a process that occurs over the meter scale of measurement of multiple year and requires the accruement of multiple viral mutations , " Jesse Bloom , an evolutionary life scientist at the Fred Hutchinson Cancer Research Center in Seattle , order the Times . " It ’s not going to be like an on - off switch , " in terms of how rapidly new version become resistant to current vaccines , he said . In other words , vaccines might become gradually less good over time , rather than suddenly not working .
Originally publish on Live Science .
